Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Centessa Pharmaceuticals (CNTA) Consolidated Net Income (2022 - 2025)

Historic Consolidated Net Income for Centessa Pharmaceuticals (CNTA) over the last 4 years, with Q3 2025 value amounting to -$54.9 million.

  • Centessa Pharmaceuticals' Consolidated Net Income fell 2895.5% to -$54.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$242.7 million, marking a year-over-year decrease of 5049.64%. This contributed to the annual value of -$235.8 million for FY2024, which is 5604.26% down from last year.
  • Latest data reveals that Centessa Pharmaceuticals reported Consolidated Net Income of -$54.9 million as of Q3 2025, which was down 2895.5% from -$50.3 million recorded in Q2 2025.
  • Centessa Pharmaceuticals' 5-year Consolidated Net Income high stood at -$24.9 million for Q2 2023, and its period low was -$111.3 million during Q4 2024.
  • In the last 4 years, Centessa Pharmaceuticals' Consolidated Net Income had a median value of -$43.8 million in 2024 and averaged -$49.0 million.
  • Its Consolidated Net Income has fluctuated over the past 5 years, first surged by 6151.31% in 2023, then tumbled by 20222.06% in 2024.
  • Centessa Pharmaceuticals' Consolidated Net Income (Quarter) stood at -$43.2 million in 2022, then increased by 14.68% to -$36.8 million in 2023, then tumbled by 202.22% to -$111.3 million in 2024, then skyrocketed by 50.69% to -$54.9 million in 2025.
  • Its Consolidated Net Income stands at -$54.9 million for Q3 2025, versus -$50.3 million for Q2 2025 and -$26.1 million for Q1 2025.